Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H24N2.C4H4O4 |
Molecular Weight | 408.4901 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C3=CC=CC=N3
InChI
InChIKey=SWECWXGUJQLXJF-BTJKTKAUSA-N
InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula | C20H24N2 |
Molecular Weight | 292.418 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB08801
Sources: https://www.drugbank.ca/drugs/DB08801
Dimetindene (trade name Fenistil; other name dimethindene maleate) is a potent antipruritic antihistamine, characterized by the small size of its effective dose and its rapidity of action. Dimetindene is an antihistamine/anticholinergic that is a selective H1 antagonist. Its effect sets in after 20 to 60 minutes and lasts several hours. Dimetindene drops as well as Dimetindene syrup is particularly indicated in pediatric practice. Dimetindene is indicated as symptomatic treatment of allergic reactions: urticaria, allergies of the upper respiratory tract such as hay fever and perennial rhinitis, food, and drug allergies; pruritus of various origins, except pruritus due to cholestasis; insect bites. Dimetindene is also indicated for pruritus in eruptive skin diseases such as chicken-pox. Dimetindene can be as an adjuvant in eczema and other pruriginous dermatoses of allergic origin.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12593665 |
0.692 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
||
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
||
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
101.3 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.41 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.28 mg 2 times / day multiple, intranasal Recommended Dose: 0.28 mg, 2 times / day Route: intranasal Route: multiple Dose: 0.28 mg, 2 times / day Sources: |
unhealthy, 18 -69 n = 76 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 18 -69 Sex: M+F Population Size: 76 Sources: |
|
0.1 % 1 times / day single, topical Highest studied dose Dose: 0.1 %, 1 times / day Route: topical Route: single Dose: 0.1 %, 1 times / day Sources: |
healthy, 33 (21-54) n = 24 Health Status: healthy Age Group: 33 (21-54) Sex: M+F Population Size: 24 Sources: |
|
6 mg 1 times / day single, oral Highest studied dose Dose: 6 mg, 1 times / day Route: oral Route: single Dose: 6 mg, 1 times / day Sources: |
healthy, adult n = 60 Health Status: healthy Age Group: adult Sex: M Population Size: 60 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Antimycobacterial antihistaminics]. | 1989 Aug |
|
Are hypotension and rash after atracurium really caused by histamine release? | 1994 May |
|
[Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation]. | 1996 May |
|
Neuronal soma-dendritic and prejunctional M1-M4 receptors in gastrointestinal and genitourinary smooth muscle. | 1999 |
|
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. | 2002 Jul 1 |
|
Anti-inflammatory efficacy of topical preparations with 10% hamamelis distillate in a UV erythema test. | 2002 Mar-Apr |
|
[Mesenteric traction syndrome during the operation of aneurysms of the abdominal aorta--histamine release and prophylaxis with antihistaminics]. | 2003 |
|
Influence of peak measurement parameters on the quality of chiral electrophoretic separations. | 2003 Aug |
|
Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists. | 2003 Feb 27 |
|
Effects of dimethindene maleate nasal spray on the quality of life in seasonal allergic rhinitis. | 2003 Sep |
|
Influence of methanol on the enantioresolution of antihistamines with carboxymethyl-beta-cyclodextrin in capillary electrophoresis. | 2004 Aug |
|
Premedication with H1 and H2 blocking agents reduces the incidence of postoperative nausea and vomiting. | 2004 Aug |
|
Anaphylaxis to intravenous sinistrin. | 2004 Dec |
|
Differential effects of organic modifiers on the enantioseparation of dimetindene maleate with carboxymethyl-beta-cyclodextrin in capillary electrophoresis. | 2004 Jan |
|
[Systemic mastocytosis. Classification, symptoms, therapy]. | 2004 Mar 15 |
|
[Dimethindene determination in various dosage forms by means of capillary isotachophoresis]. | 2005 Sep |
|
Spectrophotometric determination of some antihistaminic drugs using 7,7,8,8-tetracyanoquinodimethane (TCNQ). | 2006 Jan-Feb |
|
Comparison of capillary zone electrophoresis and isotachophoresis determination of dimethindene enantiomers in pharmaceuticals using charged carboxyethyl-beta-cyclodextrin as a chiral selector. | 2006 Nov |
|
A simplified premedication protocol for one-hour paclitaxel infusion in various combinations. | 2006 Nov |
|
[Aso an inspection of the family dog is warrented here]. | 2006 Oct 19 |
|
Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. | 2007 Apr 20 |
|
Determination of dimethindene enantiomers in pharmaceuticals by capillary electrophoresis with carboxyethyl-beta-cyclodextrin. | 2007 Jan |
|
Chiral separation of alkylamine antihistamines in pharmaceuticals by capillary isotachophoresis with charged cyclodextrin. | 2007 Nov |
|
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. | 2009 |
|
Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs. | 2009 Dec |
|
The basophil activation test in the diagnosis of allergy: technical issues and critical factors. | 2009 Sep |
|
Permeability alterations after surgical trauma in normal rabbit peritoneum. | 2010 |
|
Immunoglobulin E-mediated anaphylaxis to rabeprazole. | 2010 |
|
Garlic-induced severe anaphylaxis in a nonatopic patient. | 2010 |
|
Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats. | 2010 Apr |
|
10-year-old girl with severe edema caused by adder bite. | 2010 Dec |
|
Prevention of postoperative adhesion formation by individual and combined administration of 4 per cent icodextrin and dimetindene maleate (Br J Surg 2009; 96: 1476-1483). | 2010 Mar |
|
Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b. | 2010 May |
|
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. | 2010 Oct 1 |
|
CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://pcm.me/fenistil-%C2%AE/
Drops: Infants up to 1 year, 10-30 drops; Infants of 1 to 3 years, 30-45 drops; Children over 3 years, 45-60 drops; Adults, 60-120 drops.
Syrup: Infants up to 1 year, 1-3 teaspoons; Infants of 1 to 3 years, 3-4 teaspoons; Children over 3 years, 4-6 teaspoons; Adults, 6-12 teaspoons. 1 teasponful Fenistil syrup = 5ml = 0.5mg
Coated tablets: Adults, 3-6 tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6832322
Experiments were carried out on isolated right ventricular papillary muscle of cat and guinea-pig, and on left atrial muscle of guinea-pig. The animals were anesthetized
with ether, and the muscles were dissected from the heart as quickly as possible and mounted in an organ chamber. The preparations were driven electrically at 2.0 or 0.5 Hz. The transmembrane potentials were recorded by means of conventional glass microelectrode technique. The slow response APs were elicited with histamine (10^-5 M) ) or caffeine (2 mM) in partially depolarized (up to -40 mV) left atrial and right ventricular.myocardium of guinea-pigs. The membrane was depolarized by means of elevated K + (26 mM)-Krebs solution. Dimetindene was freshly dissolved and added to the organ chamber containing Krebs solution (composition in mM): NaC1 118, KCl 4.7, CaC12 2.5, NaH2PO4 1.0, MgC12 1.2, NaHCO3 24.9, glucose 11.5, which was gassed with 95% 02 and 5% CO2 and kept at 37C
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:47:30 UTC 2023
by
admin
on
Fri Dec 15 16:47:30 UTC 2023
|
Record UNII |
6LL60J9E0O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
107677
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
258334
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL22108
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
222-789-2
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
6LL60J9E0O
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
3614-69-5
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
C76674
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
DBSALT000908
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
m4508
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | Merck Index | ||
|
5282414
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
100000087512
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY | |||
|
SUB01754MIG
Created by
admin on Fri Dec 15 16:47:31 UTC 2023 , Edited by admin on Fri Dec 15 16:47:31 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |